Building a Fit-for-Purpose TPD Biomarker: Kinesin Quantification in PBMCs from Discovery Through Clinical Development
11:20 am - Wednesday 7th October 2026
- Discovery proteomics identified KIF22 peptides that quantify target abundance directly in PBMCs, and degrader-treated cell models confirmed selective loss of signal, establishing a repeatable, minimally invasive measure of degradation
- Blood collection, PBMC isolation, and sample handling variables were characterized to define the conditions under which KIF22 measurement holds, translating into handling requirements that clinical sites can execute reproducibly
- A targeted PRM assay quantifies KIF22 with high sensitivity and reproducible performance across donor matrices, supporting fit-for-purpose validation and pharmacodynamic assessment in early-phase development
